Newcastle University

Roles and Responsibilities

Management of Pharmacology group
Liaison with Medical Oncology

Qualifications

PhD Pharmacokinetics, Manchester 1986

Memberships

BACR
AACR

Research Interests

Pharmacokinetics and metabolism of anticancer drugs

• Veal GJ, Errington J, Rowbotham SE, Illingworth NA, Malik G, Cole M, Daly AK, Pearson ADJ, Boddy AV. Adaptive dosing approaches to the individualization of 13-cis-retinoic acid (isotretinoin) treatment for children with high-risk neuroblastoma. Clinical Cancer Research 2013, 19(2), 469-479.
• Hill CR, Jamieson D, Thomas HD, Brown CDA, Boddy AV, Veal GJ. Characterisation of the roles of ABCB1, ABCC1, ABCC2 and ABCG2 in the transport and pharmacokinetics of actinomycin D in vitro and in vivo. Biochemical Pharmacology 2013, 85(1), 29-37.
• Kontny NE, Wurthwein G, Joachim B, Boddy AV, Krischke M, Fuhr U, Thompson PA, Jorger M, Schellens JHM, Hempel G. Population pharmacokinetics of doxorubicin: establishment of a NONMEM model for adults and children older than 3 years. Cancer Chemotherapy and Pharmacology 2013, 71(3), 749-763.
• Veal GJ, Boddy AV. Carboplatin dosing in infants with retinoblastoma: a case for therapeutic drug monitoring. Journal of Clinical Oncology 2012, 30(27), 3424.
• Veal GJ, Boddy AV. Chemotherapy in newborns and preterm babies. Seminars in Fetal and Neonatal Medicine 2012, 17(4), 243-248.
• Kontny NE, Boos J, Wurthwein G, Hempel G, Boddy AV, Groll AH, Krischke M. Minimization of the Preanalytical Error in Pharmacokinetic Analyses and Therapeutic Drug Monitoring: Focus on IV Drug Administration. Therapeutic Drug Monitoring 2012, 34(4), 460-466.
• Jarvis IWH, Meczes EL, Thomas HD, Edmondson RJ, Veal GJ, Boddy AV, Ottley CJ, Pearson DG, Tilby MJ. Therapy induced carboplatin-DNA adduct levels in human ovarian tumours in relation to assessment of adduct measurement in mouse tumours. Biochemical Pharmacology 2012, 83(1), 69-77.
• Plummer R, Wilson RH, Calvert H, Boddy AV, Griffin M, Sludden J, Tilby MJ, Eatock M, Pearson DG, Ottley CJ, Matsumura Y, Kataoka K, Nishiya T. A Phase I clinical study of cisplatin-incorporated polymeric micelles (NC-6004) in patients with solid tumours. British Journal of Cancer 2011, 104(4), 593-598.
• Illingworth NA, Boddy AV, Daly AK, Veal GJ. Characterisation of the metabolism of fenretinide by human liver microsomes, cytochrome P450 enzymes and UDP-glucuronosyltransferases. British Journal of Pharmacology 2011, 162(4), 989-999.
• Jamieson D, Boddy AV. Pharmacogenetics of genes across the doxorubicin pathway. Expert Opinion on Drug Metabolism and Toxicology 2011, 7(10), 1201-1210.
• Chinnaswamy G, Errington J, Foot A, Boddy AV, Veal GJ, Cole M. Pharmacokinetics of cyclophosphamide and its metabolites in pediatric patients receiving high-dose myeloablative therapy. European Journal of Cancer 2011, 47(10), 1556-1563.
• Chinnaswamy G, Errington J, Foot A, Boddy AV, Veal GJ, Cole M. Pharmacokinetics of high-dose cyclophosphamide and its metabolites in paediatric patients. In: Pediatric Blood & Cancer: 43rd Congress of the International Society of Paediatric Oncology (SIOP). 2011, Auckland, New Zealand: John Wiley & Sons, Inc.
• Green S, Phoenix B, Mill AJ, Hill M, Charles MW, Thompson J, Jones B, Ngoga D, Detta A, James ND, Doran J, Graham N, Ghani Z, Wojnecki C, Halbert G, Elliott M, Ford S, Sheehan TMT, Vickerman J, Lockyer N, Croswell G, Boddy A, King A, Cruickshank GS. The Birmingham Boron Neutron Capture Therapy (BNCT) Project: Developments towards Selective Internal Particle Therapy [abstract]. Clinical Oncology 2011, 23(3), S23-S24.
• Pridgeon SW, Heer R, Taylor GA, Newell DR, O'Toole K, Robinson M, Xu YZ, Karran P, Boddy AV. Thiothymidine combined with UVA as a potential novel therapy for bladder cancer. British Journal of Cancer 2011, 104(12), 1869-1876.
• Jamieson D, Cresti N, Bray J, Sludden J, Griffin MJ, Hawsawi NM, Famie E, Mould EVA, Verrill MW, May FEB, Boddy AV. Two minor NQO1 and NQO2 alleles predict poor response of breast cancer patients to adjuvant doxorubicin and cyclophosphamide therapy. Pharmacogenetics and Genomics 2011, 21(12), 808-819.
• Podesta JE, Griffin MJ, Sugar R, Squires MS, Boddy A, Linardopoulos S, Pearson ADJ, Moore AS. Adaptation and Validation of the Plasma Inhibitory Activity (PIA) Assay to Detect Inhibition of Aurora, ABL and FLT3 kinases by AT9283 In Children and Adolescents with Leukaemia. In: Blood: 52nd Annual Meeting of the American Society of Hematology. 2010, Orlando, Florida, USA: American Society of Hematology.
• Mondick JT, Gibiansky L, Gastonguay MR, Skolnik JM, Cole M, Veal GJ, Boddy AV, Adamson PC, Barrett JS. Population pharmacokinetic investigation of actinomycin D in children and young adults. Journal of Clinical Pharmacology 2008, 48(1), 35-42.
• Yule, S., Price, L., McMahon, A., Pearson, A. D. J., Boddy, A. V. Cyclophosphamide Metabolism in Children with Non-Hodgkin's Lymphoma. Clinical Cancer Research 2004, 10(2), 455-460.
• Cole M, Price L, Parry AP, Keir M, Pearson ADJ, Boddy A V, Veal GJ. Estimation of glomerular filtration rate in paediatric cancer patients using ⁵¹CR-EDTA population pharmacokinetics. British Journal of Cancer 2004, 90(1), 60-64.
• Wells, P., Aboagye, E., Gunn, R., Osman, S., Boddy, A. V., Taylor, G. A., Rafi, I., Hughes, A. N., Calvert, A. H., Price, P., Newell, D. R. 2-[¹¹C]thymidine positron emission tomography as an indicator of thymidylate synthase inhibition in patients treated with AG337. Journal of the National Cancer Institute 2003, 95(9), 675-682.
• Veal, G. J., Coulthard, S., Boddy, A. V. Chemotherapy individualization. Investigational New Drugs 2003, 21(2), 149-156.
• Veal, G. J., Errington, J., Sludden, J., Griffin, M. J., Price, L., Parry, A. P., Hale, J. P., Pearson, A. D. J., Boddy, A. V. Determination of anti-cancer drug actinomycin D in human plasma by liquid chromatography-mass spectrometry. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences 2003, 795(2), 237-243.
• Veal, G. J., Errington, J., Redfern, C., Pearson, A. D. J., Boddy, A. V. Influence of isomerisation on the growth inhibitory effects and cellular activity of 13-cis and all-trans retinoic acid in neuroblastoma cells. Biochemical Pharmacology 2002, 63(2), 207-215.
• Hughes AN, Calvert PM, Azzabi A, Plummer ER, Johnson R, Rusthoven J, Griffin MJ, Fishwick KA, Boddy AV, Verrill MW, Calvert AH. Phase I clinical and pharmacokinetic study of pemetrexed and carboplatin in patients with malignant pleural mesothelioma. Journal of Clinical Oncology 2002, 20(16), 3533-3544.
• Batey MA, Wright JG, Azzabi A, Newell DR, Lind MJ, Calvert AH, Boddy AV. Population pharmacokinetics of adjuvant cyclophosphamide, methotrexate and 5-fluorouracil (CMF). European Journal of Cancer 2002, 38(8), 1081-1089.
• Thomas HD, Porter D, Bartelink I, Nobbs J, Cole M, Elliott S, Newell DR, Calvert AH, Highley M, Boddy AV. Randomized cross-over clinical trial to study potential pharmacokinetic interactions between cisplatin or carboplatin and etoposide. British Journal of Clinical Pharmacology 2002, 53(1), 83-91.
• Simpson, A. B., Calvert, P. M., Sludden, J., Boddy, A. V., Griffin, M. J., Schatzlein, A., Wilson, P., Fishwick, K., Wheatley, A., Ross, G. A., Calvert, A. H., Twelves, C. J. Topotecan in combination with carboplatin: phase I trial evaluation of two treatment schedules. Annals of Oncology 2002, 13(3), 399-402.
• Veal, G. J., Griffin, M., Price, E., Parry, A. P., Dick, G., Little, M., Yule, S., Morland, B., Estlin, E., Hale, J. P., Pearson, A. D. J., Welbank, H., Boddy, A. V. A phase I study in paediatric patients to evaluate the safety and pharmacokinetics of SPI-77, a liposome encapsulated formulation of cisplatin. British Journal of Cancer 2001, 84(8), 1029-1035.
• Estlin, E. J., Pinkerton, C. R., Lewis, I. J., Lashford, L., McDowell, H., Morland, B., Kohler, J., Newell, D. R., Boddy, A. V., Taylor, G. A., Price, L., Ablett, S., Hobson, R., Pitsiladis, M., Brampton, M., Clendeninn, N., Johnston, A., Pearson, A. D. J. A phase I study of nolatrexed dihydrochloride in children with advanced cancer. A United Kingdom Children's Cancer Study Group Investigation. British Journal of Cancer 2001, 84(1), 11-18.
• Wright, J., Boddy, A. V. All half-lives are wrong, but some half-lives are useful. Clinical Pharmacokinetics 2001, 40(4), 237-244.
• Sharkey, I., Boddy, A. V., Wallace, H., Mycroft, J., Hollis, R., Picton, S. Body surface area estimation in children using weight alone: Application in paediatric oncology. British Journal of Cancer 2001, 85(1), 23-28.
• Patoux, A., Bleyzac, N., Boddy, A. V., Doz, F., Rubie, H., Bastian, G., Maire, P., Canal, P., Chatelut, E. Comparison of nonlinear mixed-effect and non-parametric expectation maximisation modelling for Bayesian estimation of carboplatin clearance in children. European Journal of Clinical Pharmocology 2001, 57(4), 297-303.
• Yule SM, Price L, Cole M, Pearson ADJ, Boddy AV. Cyclophosphamide metabolism in children following a 1-h and a 24-h infusion. Cancer Chemotherapy and Pharmacology 2001, 47(3), 222-228.
• Wright, J., Boddy, A. V., Highley, M., Fenwick, J., McGill, A., Calvert, A. H. Estimation of glomerular filtration rate in cancer patients. British Journal of Cancer 2001, 84(4), 452-459.
• Veal, G. J., Dias, C., Price, L., Parry, A. P., Errington, J., Hale, J. P., Pearson, A. D. J., Boddy, A. V., Newell, D. R., Tilby, M. J. Influence of cellular factors and pharmacokinetics on the formation of platinum-DNA adducts in leukocytes of children receiving cisplatin therapy. Clinical Cancer Research 2001, 7(8), 2205-2212.
• Boddy AV, Griffin MJ, Sludden J, Thomas HD, Fishwick KA, Wright J, Plummer ER, Highley MS, Calvert AH. Pharmacological study of paclitaxel duration of infusion combined with GFR-based carboplatin in the treatment of ovarian cancer. Cancer Chemotherapy and Pharmacology 2001, 48(1), 15-21.
• Lu, X., Errington, J., Chen, V., Curtin, N. J., Boddy, A. V., Newell, D. R. Cellular ATP depletion by LY309887 as a predictor of growth inhibition in human tumor cell lines. Clinical Cancer Research 2000, 6(1), 271-277.
• Hughes, A. N., Griffin, M. J., Newell, D. R., Calvert, A. H., Johnston, A., Kerr, B., Lee, C., Liang, B., Boddy, A. V. Clinical pharmacokinetic and in vitro combination studies of nolatrexed dihydrochloride (AG337, Thymitaq(TM)) and paclitaxel. British Journal of Cancer 2000, 82(9), 1519-1527.
• Johnstone EC, Griffin MJ, Lind MJ, Boddy AV. Ifosfamide metabolism and DNA damage in tumour and peripheral blood lymphocytes of breast cancer patients. Cancer Chemotherapy and Pharmacology 2000, 46(6), 433-441.
• Boddy, A. V., Yule, S. M. Metabolism and pharmacokinetics of oxazaphosphorines. Clinical Pharmacokinetics 2000, 38(4), 291-304.
• Thomas HD, Lind M, Ford J, Bleehen N, Calvert AH, Boddy AV. Pharmacokinetics of carboplatin administered in combination with the bradykinin agonist Cereport (RMP-7) for the treatment of brain tumours. Cancer Chemotherapy and Pharmacology 2000, 45(4), 284-290.
• Thomas HD, Boddy AV, English M, Hobson R, Imeson J, Lewis I, Morland B, Pearson ADJ, Pinkerton R, Price L, Stevens M, Newell DR. Prospective validation of renal function-based carboplatin dosing in children with cancer: A United Kingdom Children's Cancer Study Group Trial. Journal of Clinical Oncology 2000, 18(21), 3614-3621.
• Lu, X., Errington, J., Lunec, J., Chen, V. J., Curtin, N. J., Boddy, A. V., Newell, D. R. GARFT inhibitor LY309887 cytotoxicity correlates with ATP depletion but not with p53 status in human tumour cell lines. In: BRITISH JOURNAL OF CANCER. 1999.
• Jodrell, D., Bowman, A., Rye, R., Byrne, B., Boddy, A. V., Rafi, I., Taylor, G., Johnston, A., Clendeninn, N. A phase I study of the lipophilic thymidylate synthase inhibitor Thymitaq® (nolatrexed dihydrochloride) given by 10-day oral administration. British Journal of Cancer 1999, 79(5/6), 915-920.
• Yule, S. M., Price, L., Cole, M., Pearson, A. D. J., Boddy, A. V. Cyclophosphamide metabolism in children with Fanconi's anaemia. Bone Marrow Transplantation 1999, 24(2), 123-128.
• Hughes, A. N., Rafi, I., Griffin, M. J., Calvert, A. H., Newell, D. R., Calvete, J., Johnston, A., Clendeninn, N., Boddy, A. V. Phase I studies with the nonclassical antifolate nolatrexed dihydrochloride (AG337, THYMITAQ) administered orally for 5 days. Clinical Cancer Research 1999, 5(1), 111-118.
• Cerny, T., Leyvraz, S., von Briel, T., Kupfer, A., Schaad, R., Schmitz, S. F. H., Honegger, P., Sessa, C., Brunner, J., Boddy, A. V. Saturable metabolism of continuous high-dose ifosfamide with Mesna and GM-CSF: A pharmacokinetic study in advanced sarcoma patients. Annals of Oncology 1999, 10(9), 1087-1094.
• Yule, S. M., Walker, D., Cole, M., McSorley, L., Cholerton, S., Daly, A. K., Pearson, A. D. J., Boddy, A. V. The effect of fluconazole on cyclophosphamide metabolism in children. Drug Metabolism and Disposition 1999, 27(3), 417-421.
• Bisogno G, Cowie F, Boddy AV, Thomas HD, Dick G, Pinkerton C. High dose cyclosporin with etoposide - Toxicity and pharmacokinetic interaction in children with solid tumours. British Journal of Cancer 1998, 77(12), 2304-2309.
• Vigushin, D., Poon, G., Boddy, A. V., English, J., Halbert, G., Pagonis, C., Jarman, M., Coombes, R. Phase I and pharmacokinetic study of D-limonene in patients with advanced cancer. Cancer Chemotherapy and Pharmacology 1998, 42(2), 111-117.
• Rafi, I., Boddy, A. V., Calvete, J., Taylor, G. A., Newell, D. R., Bailey, N. P., Lind, M., Green, M., Hines, J., Johnstone, A., Clendeninn, N., Calvert, A. H. Preclinical and phase I clinical studies with the nonclassical antifolate thymidylate synthase inhibitor nolatrexed dihydrochloride given prolonged administration in patients with solid tumors. Journal of Clinical Oncology 1998, 16(3), 1131-1141.
• Siddiqui N, Boddy AV, Thomas HD, Bailey N, Robson L, Lind M, Calvert AH. A clinical and pharmacokinetic study of the combination of carboplatin and paclitaxel for epithelial ovarian cancer. British Journal of Cancer 1997, 75(2), 287-294.
• Peng, B., English, M. W., Boddy, A. V., Price, L, Wyllie, R., Pearson, A. D. J. , Tilby, M. J., Newell, D. R. Cisplatin pharmacokinetics in children with cancer. European Journal of Cancer 1997, 33(11), 1823-1828.
• Yule, S., Price, L., Pearson, A. D. J., Boddy, A. V. Cyclophosphamide and ifosfamide metabolites in the cerebrospinal fluid of children. Clinical Cancer Research 1997, 3(11), 1985-1992.
• Boddy, A. V., Ratain, M. Pharmacogenetics in cancer etiology and chemotherapy. Clinical Cancer Research 1997, 3(7), 1025-1030.
• Boddy AV, Thomas HD. RMP-7. Potential as an adjuvant to the drug treatment of brain tumours. CNS Drugs 1997, 7(4), 257-263.
• English, M., Lowis, S., Peng, B., Boddy, A. V., Newell, D. R., Price, L., Pearson, A. D. J. Pharmacokinetically guided dosing of carboplatin and etoposide during peritoneal dialysis and haemodialysis. British Journal of Cancer 1996, 73(6), 776-780.
• Chatelut, E., Boddy, A. V., Peng, B., Rubie, H., Lavit, M., Dezeuze, A., Pearson, A. D. J., Roche, H., Robert, A., Newell, D. R., Canal, P. Population pharmacokinetics of carboplatin in children. Clinical Pharmacology and Therapeutics 1996, 59(4), 436-443.
• Calvert AH, Boddy AV, Bailey NP, Siddiqui N, Humphreys A, Hughs A, Robson L, Gumbrell L, Thomas H, Chapman F, Proctor M, Simmons D, Oakey A, Lind MJ, Sinha DV, Newell DR. Carboplatin in combination with paclitaxel in advanced ovarian cancer: dose determination and pharmacokinetic and pharmacodynamic interactions. Seminars in Oncology 1995, 22(5 Suppl. 12), 91-98.
• Rafi, I., Taylor, G. A., Calvete, J. A., Boddy, A. V., Balmanno, K., Bailey, N., Lind, M., Calvert, A. H., Webber, S., Jackson, R. C., Johnston, A., Clendeninn, N., Newell, D. R. Clinical pharmacokinetic and pharmacodynamic studies with the nonclassical antifolate thymidylate synthase inhibitor 3,4-dihydro-2-amino-6-methyl-4-oxo-5-(4-pyridplthio)-quinazolone dihydrochloride (AG337) given by 24-hour continuous intravenous infusion. Clinical Cancer Research 1995, 1(11), 1275-1284.
• Wedge SR, Laohavinij S, Taylor GA, Boddy AV, Calvert AH, Newell DR. Clinical pharmacokinetics of the antipurine antifolate (6R)-5,10-dideaza-5,6,7,8-tetrahydrofolic acid (lometrexol) administered with an oral folic acid supplement. Clinical Cancer Research 1995, 1(12), 1479-1486.